Efficacy of fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer: A preliminary report

Journal of Breast Cancer

Volumn 14, Issue 2, 2011, Pages 135-139

  Yoo, Changhoon ^a   Kim, Sung Bae ^a   Ahn, Jin Hee ^a   Jung, Kyung Hae ^a   Ahn, Yongchel ^a   Gong, Gyungyub ^a   Kim, Hak Hee ^a   Kim, Hee Jung ^a   Son, Byung Ho ^a   Ahn, Sei Hyun ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Endocrine therapy; Fulvestrant

Indexed keywords

EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; KOREA; MULTIPLE CYCLE TREATMENT; MYALGIA; OVERALL SURVIVAL; POSTMENOPAUSE; SWELLING; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79959841052     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2011.14.2.135     Document Type: Article

References (18)

1. Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004; 90 Suppl 1:S2-6.
2. Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer 2002;87:1354-1359.
3. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-750.
4. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-3395.
5. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20: 3396-3403.
6. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-1670.
7. Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, et al. Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme. Breast Cancer Res Treat 2007;106:105-112.
8. Steger GG, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, et al. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 2005;41:2655-2661.
9. Safra T, Greenberg J, Ron IG, Ben-Yosef R, Inbar M, Sarid D, et al. Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment? Isr Med Assoc J 2008;10:339-343.
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
11. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
12. Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-4535.
13. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-1613.
14. Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104:236-239.
15. Robertson JF. Fulvestrant (Faslodex): how to make a good drug better. Oncologist 2007;12:774-784.
16. di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko I, Khasanov R, et al. Confirm: a phase III, randomized, parallel-group trial comparing fulvestrant 250 mg vs fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. Cancer Res 2009;69(24 Suppl):Abstract #25.
17. Young OE, Renshaw L, Macaskill EJ, White S, Faratian D, Thomas JS, et al. Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 2008;44:391-399.
18. Matsuno RK, Anderson WF, Yamamoto S, Tsukuma H, Pfeiffer RM, Kobayashi K, et al. Early- and late-onset breast cancer types among women in the United States and Japan. Cancer Epidemiol Biomarkers Prev 2007;16:1437-1442.